Athersys (NASDAQ:ATHX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Athersys has a 1 year low of $0.01 and a 1 year high of $1.99. The firm has a market capitalization of $833,000.00, a P/E ratio of -0.01 and a beta of -0.90.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.